COMMITMENTS AND CONTINGENCIES (Details Narrative)										1 Months Ended				3 Months Ended	12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 10, 2021 USD ($)	Oct. 18, 2021 USD ($) shares	Jun. 10, 2021 ft²	Jan. 02, 2021 USD ($)	Sep. 24, 2020 USD ($)	Jul. 05, 2020 USD ($) shares	Jun. 05, 2020 USD ($) shares	Aug. 31, 2017 USD ($)	Jun. 30, 2020 shares	Dec. 31, 2019	Mar. 31, 2018 USD ($)	Sep. 30, 2006 USD ($)	Mar. 31, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) $ / shares shares	Sep. 22, 2020 shares
Loss Contingencies [Line Items]
Subscription payable															$ 1,350,000
Settlement of accounts payable			$ 42,120
Common Stock, Shares Authorized | shares														12,000,000,000	12,000,000,000	6,666,667
Accounts Payable, Current														$ 847,070	$ 1,018,797
Business Combination, Contingent Consideration, Liability														74,840	71,240
Debt Instrument, Face Amount														2,000,000
Accrued interest payable														34,840	31,240
Loss Contingency, Damages Awarded, Value									$ 1,000,000
Two Notes Payable [Member]
Loss Contingencies [Line Items]
Debt Instrument, Face Amount														40,000	40,000
Minimum [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value		$ 100,000,000
Busch Employment Agreement [Member]. | Restricted Stock Units (RSUs) [Member]
Loss Contingencies [Line Items]
Accrued Salaries														162,500	132,500
Exclusive License Agreement [Member] | George Mason University [Member]
Loss Contingencies [Line Items]
Royalty Expense													$ 50,000
Revenue, percentage													1.50%
Advance Royalties														1,739	1,591
Exclusive License Agreement [Member] | Sublicense Royalty [Member] | George Mason University [Member]
Loss Contingencies [Line Items]
Revenue, percentage													15.00%
License Agreement [Member] | National Institutes of Health [Member]
Loss Contingencies [Line Items]
Royalty Expense												$ 1,000
Revenue, percentage												3.00%
Advance Royalties														27,330	$ 24,830
Non-refundable minimum annual royalty												$ 5,000
License Agreement [Member] | Sublicense Royalty [Member] | National Institutes of Health [Member]
Loss Contingencies [Line Items]
Revenue, percentage												10.00%
Employee Incentive Stock Options [Member]
Loss Contingencies [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross | shares										1,800,000,000
Lease Agreement [Member]
Loss Contingencies [Line Items]
Lessee, Operating Lease, Term of Contract											61 months
Lease Expiration Date											Feb. 28, 2025
Lease Amendment [Member]
Loss Contingencies [Line Items]
Area of Land | ft²				4,734
Monthly rent, description				Company must pay a total annual base rent of; (1) $115,823 for year one; (2) $119,310 for year two; (3) $122,893 for year three; (4) $126,580 for year four; (5) $130,377 for year five; (6) $135,163 for year six; (7) $139,218 for year seven; (8) $143,394 for year eight; (9) $147,696 for year nine; (10) $152,127 for year ten; (11) $156,331 for year eleven; (12) $161,391 for year twelve; (13) $166,233 for year thirteen; (14) $171,220 for year fourteen and; (15) $176,357 for year fifteen
Subscription Agreement [Member]
Loss Contingencies [Line Items]
Sale of Stock, Consideration Received on Transaction														$ 1,350,000
Subscription Agreement [Member] | Common Stock [Member]
Loss Contingencies [Line Items]
Sale of Stock, Number of Shares Issued in Transaction | shares														431,309,907	431,309,907
Sale of Stock, Price Per Share | $ / shares														$ 0.00313	$ 0.00313
Sale of Stock, Consideration Received on Transaction														$ 1,350,000	$ 1,350,000
Settlement of Accounts Payable [Member]
Loss Contingencies [Line Items]
Stock Issued During Period, Shares, New Issues | shares														26,913,738
Settlement of accounts payable			$ 84,240
Common Stock, Shares Authorized | shares			26,913,738
Accounts Payable, Current														$ 84,240
Dr. Michael Ruxin [Member]
Loss Contingencies [Line Items]
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold														$ 87,500	62,500
Dr. Michael Ruxin [Member] | Ruxin Employment Agreement [Member]
Loss Contingencies [Line Items]
Annual base salary								$ 300,000
Annual decretionary bonus percentage								150.00%
Dr. Michael Ruxin [Member] | Ruxin Employment Agreement [Member] | 2020 Equity Incentive Plan [Member]
Loss Contingencies [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares								49,047,059
Dr. Michael Ruxin [Member] | Ruxin Employment Agreement [Member] | 2020 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Loss Contingencies [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross | shares								420,691,653
Jeffrey Busch [Member] | Busch Employment Agreement [Member].
Loss Contingencies [Line Items]
Annual base salary								$ 60,000
Jeffrey Busch [Member] | Busch Employment Agreement [Member]. | 2020 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Loss Contingencies [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross | shares								420,691,653
Jeffrey Busch [Member] | Busch Employment Agreement [Member]. | 2020 Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Loss Contingencies [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares								49,047,059
Thomas E Chilcott [Member] | Offer Letter [Member]
Loss Contingencies [Line Items]
Annual base salary						$ 225,000
Deferred compensation arrangements overall description						Mr. Chilcott is entitled to participate in all medical and other benefits that the Company has established for its employees. The offer letter also provides that Mr. Chilcott will be granted an option to purchase up to 94,545,096 shares of the Company’s common stock subject to terms including exercise price to be set by the Board of Directors of the Company. As of March 31, 2022, no bonus was due and no options have been granted to Mr. Chilcott
Thomas E Chilcott Three [Member]
Loss Contingencies [Line Items]
Deferred compensation arrangements overall description	The Board also approved two new bonuses for which Mr. Chilcott will be eligible: (i) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $1,000,000; and (ii) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $2,000,000 in the aggregate. During the three months ended March 31, 2022, the first tranche of bonus of $37,500 was paid. As of March 31, 2022, the second tranche of bonus of $37,500 of bonus was due to Mr. Chilcott
Thomas E Chilcott Three [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Annual base salary	$ 225,000
Thomas E Chilcott Three [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Annual base salary	$ 300,000
Consultant [Member] | Scientific Advisory Board Service Agreement [Member]
Loss Contingencies [Line Items]
Compensation fees							$ 2,000
Payments for Other Fees							$ 1,500
Consultant [Member] | Scientific Advisory Board Service Agreement [Member] | 2020 Equity Incentive Plan [Member]
Loss Contingencies [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross | shares							88,786,943							88,786,943
Consultant [Member] | Pathology Advisory Board Service Agreement [Member]
Loss Contingencies [Line Items]
Compensation fees							$ 272
Payments for Other Fees							$ 1,500
Consultant [Member] | Pathology Advisory Board Service Agreement [Member] | 2020 Equity Incentive Plan [Member]
Loss Contingencies [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross | shares							77,972,192							77,972,192
Kucharchuk [Member] | Consulting Agreement [Member]
Loss Contingencies [Line Items]
Compensation fees					$ 2,000
Accrued consulting fees														$ 0	$ 18,000
Investor [Member]
Loss Contingencies [Line Items]
Stock Issued During Period, Shares, New Issues | shares														431,309,907